


# Claims


1. A pharmaceutical composition which comprises (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, and (b) an anticholinergic agent.

2. The pharmaceutical composition according to Claim 1, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

3. The pharmaceutical composition according to Claim 1 or 2, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

4. A therapeutic agent for overactive bladder, which comprises, as active ingredients, (a)

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and (b) an anticholinergic agent, which may be administered together or separately at an interval.

5. The therapeutic agent for overactive bladder according to Claim 4, wherein

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is

(S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by formula (Ia):




(Ia)

6. The therapeutic agent for overactive bladder according to

Claim 4 or 5, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.


7. A kit which comprises (a) a first component containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, and (b) a second component containing an anticholinergic agent.

8. The kit according to Claim 7, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

9. The kit according to Claim 7 or 8, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

10. A kit for treating overactive bladder, which comprises (a) a first component containing

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide

represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and (b) a second component containing an anticholinergic agent.

11. The kit for treating overactive bladder according to Claim 10, wherein

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

12. The kit for treating overactive bladder according to Claim 10 or 11, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

13.

3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-d

ihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide  
represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, which may be administered together or separately at an interval with an anticholinergic agent.

14.

3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof according to Claim 13, wherein

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)


15.

3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof according to Claim 13 or 14, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

16. A pharmaceutical composition which comprises, as an active ingredient,

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):






(I)

or a pharmaceutically acceptable salt thereof, which may be administered together or separately at an interval with an anticholinergic agent.

17. The pharmaceutical composition according to Claim 16, wherein

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is

(S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)


18. The pharmaceutical composition according to Claim 16 or

17, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

19. A method for treating overactive bladder, which comprises administering (a)

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide

represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and (b) an anticholinergic agent, which may be administered together or separately at an interval.

20. The method for treating overactive bladder according to Claim 19, wherein

3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is

(S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)

21. The method for treating overactive bladder according to Claim 19 or 20, wherein the anticholinergic agent is/are selected from any one of or more than one of the following: oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.